Kringle PharmaKringle Pharma,Inc.4884東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

Kringle Pharma FY ending Sep 2021 results

Kringle Pharma brought in ¥289.8M in revenue.

It lost about ¥124 for every ¥100 of sales at the operating level.

Revenue changed -38.0% from the prior year.

What changed from last year

FY ending Sep 2020 → FY ending Sep 2021

FY ending Sep 2020 → FY ending Sep 2021

For every ¥100 Kringle Pharma sells, how much goes where, and how much is kept.

FY ending Sep 2021

Gross margin75.3%

Operating margin-123.5%

Net margin-103.9%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第24期(2024/10/01－2025/09/30)
ID S100XBJD2025-12-19Open
EDINET (FSA Japan)
有価証券報告書－第23期(2023/10/01－2024/09/30)
ID S100UZTE2024-12-23Open
EDINET (FSA Japan)
有価証券報告書－第22期(2022/10/01－2023/09/30)
ID S100SJA82023-12-25Open
EDINET (FSA Japan)
有価証券報告書－第21期(令和3年10月1日－令和4年9月30日)
ID S100PVFJ2022-12-26Open
EDINET (FSA Japan)
有価証券報告書－第20期(令和2年10月1日－令和3年9月30日)
ID S100N50Z2021-12-27Open
EDINET (FSA Japan)
有価証券報告書－第19期(令和1年10月1日－令和2年9月30日)
ID S100KGH22020-12-28Open

Extracted from XBRL: 34 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.